The short answer: nobody knows whether oral BPC-157 works as well as injected BPC-157. No study has compared the two in people, and no published human study has used either the oral route or the under-the-skin shot most people mean.
FDA's July briefing document says it "found no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal" routes (FDA, July 2026). So pages saying capsules are best for the gut and shots for tendons are guessing.
Status as of November 6, 2026: BPC-157 is not FDA-approved for any use and isn't on the list of substances pharmacies may compound from. An HHS interim policy published October 30 says the agency doesn't intend to act against pharmacies compounding BPC-157 acetate under set conditions. Comments are open through November 13. Nothing here is medical advice or a recommendation of any route.
Key takeaways
No head-to-head human data exists. None of the four BPC-157 records on ClinicalTrials.gov (checked November 6, 2026) compares routes.
FDA found five small human studies. Zero used the oral, under-the-skin, nasal or transdermal routes.
The one phase 1 oral trial (estimated 42 volunteers, sponsor PharmaCotherapia) logged a results submission on May 23, 2016. It was pulled back, and nothing has been posted.
The only absolute bioavailability figures I found are for muscle injection in animals: about 14% to 19% in rats and 45% to 51% in dogs.
The HHS policy lists subcutaneous, intramuscular, oral and topical BPC-157 acetate, not nasal. Oral forms need documentation of adequate bioavailability in humans.
Want the short version of what's actually approved, legal and tested? Get the free BHN cheat sheet.
BPC-157 by route: what has been tested
Route | Animal studies | Human studies | Absorption measured? | Listed in HHS policy? |
|---|---|---|---|---|
Oral | Yes, rats | One trial and one gummy study, no results posted | No | Yes, with a condition |
Under the skin (SC) | Some rodent work | None published. One pilot registered, not started | No | Yes |
Into muscle (IM) | Yes, rats and dogs | None found | Animals only | Yes |
Nasal | None found | None | No | No |
Topical | Rats (cream) | None found | No | Yes |
Rectal enema | Not reviewed here | Two studies | Mostly undetected in blood | No |
IV | Rats and dogs | Two people | Half-life in animals | No |
What did the animal studies use for each route?
In the gut and liver studies FDA reviewed, mostly oral dosing and injection into the abdominal cavity, in rats. That injection is called intraperitoneal, and it isn't the under-the-skin shot people mean.
Colon fistulas. Rats got intraperitoneal injections or BPC-157 "orally (via drinking water)." FDA says either route appeared to improve healing, but the results "should be interpreted with caution."
Diclofenac damage. Same two routes. Both prevented stomach, gut and liver lesions.
Ligament injury. Intraperitoneal, "per-oral (in drinking water)" and a thin cream were all reported as effective (Cerovecki et al., 2010).
That's the closest thing to a route comparison anywhere, and it's why people say oral "works." Hold it loosely:
Timing. These were fresh, surgically made or chemically induced injuries. FDA notes it's unknown whether treatment helps once damage is established.
No dose-response. FDA says dose-response relationships "have not been established," and the molecular targets haven't been identified.
One research circle. All three papers list Predrag Sikiric of the University of Zagreb as an author. More in BPC-157 for knees and shoulders.
What is the bioavailability of oral BPC-157?
It has never been reported. FDA says absolute bioavailability by the oral, rectal, under-the-skin and nasal routes "is unknown" even in rats and dogs.
The only formal numbers come from one 2022 study that gave BPC-157 by IV and into muscle, not by mouth. Half-life by IV was 15.2 minutes in rats and 5.27 minutes in dogs. Absolute bioavailability after muscle injection was about 14% to 19% in rats and 45% to 51% in dogs (He et al., 2022).
So injection doesn't mean everything reaches the blood, at least in those animals. And a gap that wide between species is a reason not to guess at a human figure.
Does BPC-157 survive the stomach?
Reportedly yes, and that's the real case for oral. It just doesn't settle absorption.
FDA notes BPC-157 "was reported to be resistant to hydrolysis in gastric juice in vitro," citing a 1995 report. The Zagreb group says it's stable in human gastric juice "for more than 24 h" (Sikiric et al., 2020). Most peptides don't get that far, which is why most peptides are injected.
But the stomach is only the first barrier. A 2026 narrative review says "gastric stability, while necessary, is not sufficient to establish oral bioavailability." Its authors found no published intestinal-stability data, permeability assays or liver extraction data for BPC-157. They call the idea that stomach stability alone gives useful absorption "unsupported by direct evidence" (Pharmaceutics, 2026).
What happened to the oral BPC-157 human trial?
It was registered, its results were apparently submitted, and they were withdrawn. They've never been posted.
The trial is NCT02637284. The sponsor is PharmaCotherapia d.o.o., with Hospital Ángeles Tijuana as collaborator. It was a randomized, placebo-controlled phase 1 pilot of BPC-157 tablets in an estimated 42 healthy volunteers. One stated goal was to "document the pharmacokinetics of BPC-157 after oral administration," which is the exact question here (ClinicalTrials.gov).
Status: "Unknown." Last updated December 2015.
Results: none posted. The record logs a results submission on May 23, 2016, then an "unrelease" with no date.
FDA: "There are no results posted, and we were unable to find an associated published study."
Undark reported that Croatian government records list Sikiric as an owner of PharmaCotherapia, and that a 2025 Sikiric review said the trial found the drug safe and well tolerated without citing a paper or sharing data. Undark says he didn't respond to repeated requests for the data (STAT/Undark, Feb 3, 2026).
A second oral record appeared after FDA's search. In August 2026 a supplement company registered a completed study of BPC-157 gummies: 40 active adults, 8 weeks, no placebo, no blinding. No results are posted (ClinicalTrials.gov). With no placebo group, it can't show the gummy caused any change.
Want to know if human results by route ever post? Get BHN by email.
What human studies exist, by route?
Five, per FDA, and none uses a route people use at home.
Route | Who | Design |
|---|---|---|
Rectal enema | 24 healthy people on BPC-157 (32 randomized) | Phase 1, placebo-controlled, meeting abstracts |
Rectal enema | 53 randomized with ulcerative colitis | Randomized, double-blind, meeting abstract |
Into the knee | 17 with knee pain, some also given TB4 | Retrospective chart review |
Into the bladder wall | 12 women with interstitial cystitis | Single arm, no control group |
IV | 2 healthy people | Single arm, no control group |
Source: FDA briefing, Appendix 1.
In the enema studies, BPC-157 wasn't detected in blood or was mostly below the assay's limit. FDA says the five studies "were of short duration, had small sample sizes." An October systematic review kept three of them, 30 people in total, and rated the certainty of evidence "very low" (Acta Orthop Belg, 2026).
The first registered trial of the under-the-skin route hasn't started. The University of Arkansas plans a small pilot after rotator cuff surgery, against saline, not against oral (ClinicalTrials.gov).
Is oral BPC-157 better for gut health?
Nobody has shown that in people. The logic is that a swallowed peptide reaches the gut lining directly, so it may not need to reach the blood. That's reasoning, not a finding. FDA says the mechanisms behind the rat gut results "remain unknown."
The closest human test wasn't oral. In the ulcerative colitis enema study, disease scores fell 3.2 points on BPC-157 and 1.6 on placebo. The confidence interval for that difference included zero. FDA's conclusion: "there is a lack of evidence to make a conclusion on the effectiveness of BPC-157 for treating UC." It found no oral study in those patients, and no clinical studies at all in Crohn's or celiac disease (FDA briefing). My PubMed search found no human study in irritable bowel syndrome, leaky gut or SIBO.
BPC-157 nasal spray vs injection
There's even less on nasal. The 2026 review says "no preclinical or clinical data exist for intranasal BPC-157" (Pharmaceutics, 2026). FDA "would have strong concerns" about compounded nasal sprays because nothing is known about the pump and container, which affect what gets delivered. Nasal isn't on the HHS list either.
Is oral BPC-157 safer than injection?
Unknown. FDA says the inherent immune risk of oral BPC-157 "is likely to be low," but it's still concerned about impurities. For injected and nasal forms, it says BPC-157 "may pose a significant risk for immunogenicity." All three adverse event reports FDA found through December 4, 2025 involved injectable BPC-157, though it's unclear whether BPC-157 caused those events. FDA also didn't identify animal toxicity studies by the oral, rectal, under-the-skin or nasal routes (FDA briefing). What has and hasn't been measured is in BPC-157 side effects.
Which BPC-157 routes does the HHS policy list?
Subcutaneous, intramuscular, oral and topical, for BPC-157 acetate only. HHS says enforcement discretion "is appropriate for subcutaneous, intramuscular, oral, and topical dosage forms" (HHS policy, Oct 2026). Who can make it is covered in the HHS peptide pass.
It's discretion, not approval. The notice calls the document a draft that "is not binding on HHS or the public" (Federal Register, Oct 30, 2026). Listing a route says nothing about whether it works.
Oral comes with a catch. Per HHS, a compounder of an oral form "is expected to maintain documentation" that the formulation "achieves an adequate level of oral bioavailability in humans." No human oral absorption data has been published, so how anyone meets that is an open question.
Supplement capsules aren't covered. The policy doesn't apply to "products sold as research chemicals or dietary supplements," per BakerHostetler as cited by Nutritional Outlook, Nov 2, 2026. Prices by route are in how much BPC-157 costs, and live status is on the compounding tracker.
What would settle oral vs injection?
A human pharmacokinetic study giving the same pharmaceutical-grade product by each route, with blood levels measured. I found none registered. The fastest fix would be the sponsor of NCT02637284 posting what it submitted in 2016. If that record, the gummy study or the Arkansas trial reports, I'll update this post.
Have you used more than one route? Reply and tell me what you noticed and why you picked it. No vendor names, please.
BPC-157 oral vs injection FAQ
Does oral BPC-157 work?
It has been reported to work in rats, given in drinking water or by gavage. No published study shows it works in people.
Is BPC-157 better injected or oral?
Nobody knows, because no study has compared them in humans. Rat studies compared oral with injection into the abdominal cavity, not under the skin.
How much oral BPC-157 gets absorbed?
No one has published that number. FDA says it's unknown even in rats and dogs.
Can a pharmacy compound oral BPC-157 now?
HHS says it doesn't intend to act against covered compounders who meet its conditions, and oral BPC-157 acetate is listed. Oral forms need documentation of adequate bioavailability in humans. It isn't FDA approval.
Want the short version of what's actually approved, legal and tested? Get the free BHN cheat sheet.